UIH(SH:688271)2024-10-30 08:17Financial Performance - The company's operating revenue for Q3 2024 was ¥1,620,796,921.38, a decrease of 25.00% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was -¥279,048,838.22, representing a decline of 320.57% year-over-year[2] - The basic earnings per share for Q3 2024 was -¥0.34, a decrease of 326.67% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses for Q3 2024 was -¥333,838,043.64, a decline of 899.46% year-over-year[2] - In Q3 2024, the company's net profit was CNY 658.39 million, a decrease of 38.2% compared to CNY 1.07 billion in Q3 2023[17] - The total profit for Q3 2024 was CNY 711.86 million, down 38.9% from CNY 1.17 billion in the same period last year[17] - Operating profit for Q3 2024 was CNY 717.19 million, a decline of 38.2% from CNY 1.16 billion in Q3 2023[17] Research and Development - The R&D expenditure for Q3 2024 totaled ¥617,642,888.82, an increase of 20.03% compared to the same quarter last year, accounting for 38.11% of operating revenue[4] - The company reported a significant increase in the ratio of R&D expenditure to operating revenue, up 14.30 percentage points compared to the previous year[6] - Research and development expenses for the first three quarters of 2024 amounted to CNY 1,317,598,874.67, slightly lower than CNY 1,369,570,294.31 in the previous year[16] - The company has not disclosed any new strategies or significant developments in product or technology research during this quarter[12] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was -¥1,504,818,856.68, indicating a decrease in income and collections[2] - Cash flow from operating activities for the first nine months of 2024 was CNY -1.50 billion, compared to CNY -842.08 million in the same period of 2023[20] - The total cash and cash equivalents at the end of the period decreased to 4,797,982,424.51 from 8,018,276,723.83, reflecting a decline of about 40% year-over-year[21] - The company reported a cash outflow from investment activities of CNY 19.92 billion in the first nine months of 2024, compared to CNY 18.60 billion in the same period of 2023[20] - The company reported a cash inflow from investment activities of CNY 19.04 billion in the first nine months of 2024, an increase from CNY 18.46 billion in the same period of 2023[20] - The company incurred a credit impairment loss of CNY 107.93 million in Q3 2024, compared to a gain of CNY 1.43 million in Q3 2023[17] Assets and Liabilities - The total assets at the end of Q3 2024 were ¥26,029,675,610.35, reflecting a growth of 2.74% from the end of the previous year[4] - The total liabilities increased to CNY 6,794,298,800.24 in Q3 2024, compared to CNY 6,454,724,356.28 in Q3 2023[14] - The total equity attributable to shareholders increased to CNY 19,225,126,390.64 from CNY 18,866,353,649.67, reflecting retained earnings growth[15] - The company's accounts receivable increased to ¥4,158,675,399.49 from ¥3,227,657,250.54, reflecting a growth of about 28.8%[12] - The trading financial assets decreased significantly from ¥4,919,370,861.12 to ¥2,824,171,053.62, indicating a reduction of approximately 42.6%[12] Shareholder Information - The top shareholder, Shanghai Lianying Medical Technology Group Co., Ltd., holds 167,550,968 shares, representing 20.33% of the total shares[8] - The second-largest shareholder, Shanghai Lianhe Investment Co., Ltd., owns 134,959,614 shares, accounting for 16.38%[8] - The company has not reported any significant changes in the top 10 shareholders due to margin trading activities during the reporting period[12] Operational Insights - The company continues to expand its business, particularly in overseas markets, which has led to increased sales expenses[6] - There are no reminders or additional important information regarding the company's operational status during the reporting period[12] - The report does not indicate any future guidance or outlook for the upcoming quarters[12] - The company's financial statements for the quarter are unaudited, indicating a preliminary assessment of financial performance[12] Cost Management - Total operating costs for the first three quarters of 2024 were CNY 6,608,289,860.41, down from CNY 6,729,976,932.09 in 2023, reflecting a cost reduction strategy[16] - The company reported a decrease in accounts payable to CNY 2,243,299,748.39 from CNY 1,599,694,521.21, indicating improved cash flow management[14] Accounting Standards - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[22]